...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: Zenith Epigenetics Announces Dosing of First mCRPC Patient with a Combination of ZEN-3694 + Merck’s Immune Check Point Inhibitor KEYTRUDA
Reply New Message
Back To Forum List View
Zenith Epigenetics Announces Dosing of First mCRPC Patient with a Combination of ZEN-3694 + Merck’s Immune Check Point Inhibitor KEYTRUDA
7
LongRVXer
Mar 15, 2021 08:27AM

Great news IMO - not sure how many will be recruited or how long this trial will last??? - was told this type of trial can be completed quite fast - under 60 days???

& not one share of zen being bought on the otc - odder than odd IMO.

3 Recommendations
Icon president Re: Zenith Epigenetics Announces Dosing of First mCRPC Patient with a Combination of ZEN-3694 + Merck’s Immune Check Point Inhibitor KEYTRUDA
4
BearDownAZ
Mar 15, 2021 01:12PM
Icon president Re: Zenith Epigenetics Announces Dosing of First mCRPC Patient with a Combination of ZEN-3694 + Merck’s Immune Check Point Inhibitor KEYTRUDA
3
BearDownAZ
Mar 15, 2021 01:22PM
Re: Zenith Epigenetics Announces Dosing of First mCRPC Patient with a Combination of ZEN-3694 + Merck’s Immune Check Point Inhibitor KEYTRUDA
3
fuzzyjr
Mar 15, 2021 01:57PM
Icon president Re: Zenith Epigenetics Announces Dosing of First mCRPC Patient with a Combination of ZEN-3694 + Merck’s Immune Check Point Inhibitor KEYTRUDA
8
BearDownAZ
Mar 15, 2021 09:53PM
Reply New Message
Back To Forum List View
Share
Share
New Message
Please login to post a reply